SiBionics GS3 CGM accuracy and safety in adults with T1D
What this study tests
Newly registered 15-day study comparing the GS3 real-time CGM with venous plasma reference measurements across glucose ranges in 36 adults with T1D.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-08-04.
Most recent recorded citation date: 2026-08-04. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults with T1D; see registry for full criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. The study is recruiting an estimated 36 participants in China and estimates primary completion in June 2027.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- System accuracy against reference venous plasma glucose over 15 days
- System-related safety (adverse device effects) over 15 days, per the registry
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT07745244: GS3 CGM accuracy and safety in adults with T1D · Trial registry · 2026-08-04 — RECRUITING; estimated n=36; China; primary completion June 2027. No results are posted, so manufacturer accuracy claims are not treated as trial findings.